会议回放 | hLife Café: 宿主防御肽模拟物brilacidin增强卡泊芬净抗人类致病真菌活性

Professor Gustavo H. Goldman

A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi

报告人：Gustavo H. Goldman                                                           

报告人信息：PhD in Molecular Biology at the University of Gent, Belgium in 1993. Postdoctoral fellow at the UMDNJ, USA, 1993-1994. Assistant, Associate, and full Professor at the Universidade de São Paulo (1994 to current days). Visiting professor at Vanderbilt University, USA, and Universidade do Minho and Nova de Lisboa, Portugal. Member of the American Academy of Microbiology and Brazilian Academy of Sciences. Recipient of the Moselio Schaechter from ASM and Hans Fischer Senior Professor at the Technical University of Munich, Germany. Chief Editor of Frontiers in Fungal Biology. His main research interests are related to the study of genetic determinants of Aspergillus fumigatus that are involved in virulence and pathogenicity. His laboratory is also interested in drugs that can potentiate caspofungin against A. fumigatus. The interaction between A. fumigatus and Pseudomonas aeruginosa is also a topic of interest in his laboratory.

报告摘要：Fungal infections cause more than 1.5 million deaths a year. Due to emerging antifungal drug resistance, novel strategies are urgently needed to combat life-threatening fungal diseases. Here, we identify the host defense peptide mimetic, brilacidin (BRI) as a synergizer with caspofungin (CAS) against CAS-sensitive and CAS-resistant isolates of Aspergillus fumigatus, Candida albicans, Candida auris, and CAS-intrinsically resistant Cryptococcus neoformans. BRI also potentiates azoles against A. fumigatus and several Mucorales fungi. BRI acts in A. fumigatus by affecting cell wall integrity pathway and cell membrane potential. BRI combined with CAS significantly clears A. fumigatus lung infection in an immunosuppressed murine model of invasive pulmonary aspergillosis. BRI alone also decreases A. fumigatus fungal burden and ablates disease development in a murine model of fungal keratitis. Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections.

hLife封面合集

往期推荐

往期合集

期刊简介

hLife由高福院士、董晨院士和Jules A. Hoffmann教授（2011诺奖获得者）领衔，是中国科学院微生物研究所主办，中国生物工程学会，浙江大学陈廷骅大健康学院，西湖大学医学院，上海市免疫治疗创新研究院和广州霍夫曼免疫研究所联合支持，与国际出版商爱思唯尔合作的健康科学领域综合性英文期刊。

hLife聚焦健康科学领域的前沿进展，旨在促进基础研究与临床应用的融合发展。期刊发表与医学相关各研究领域最新成果，学科领域包括（但不限于）病原生物学、流行病学、生理学、免疫学、结构生物学、疾病监测、肿瘤、药物、疫苗和健康政策等。

hLife是一本金色开放获取期刊，月刊出版；2022年成功入选“中国科技期刊卓越行动计划高起点新刊”；2023年11月正式创刊; 2024年5月被DOAJ收录；2024年8月被Scopus收录。

2026年前hLife接受的稿件免收文章处理费（APC）。

期刊特点

诚邀投稿

我们诚邀您将高质量的健康科学相关科研成果投至hLife。

投稿网址

作者指南

期刊主页

hLife